Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurogen (NRGN) -- Ignore unavailable to you. Want to Upgrade?

To: Thomas M. who wrote (155)	3/26/1998 8:24:00 PM
From: Justa Werkenstiff	Read Replies (1) \| Respond to of 523

Thomas: You are right. Progress has been glacial. The reason the price is lagging is because this is a news driven investment because the company has no earnings. No news = no price movement. That NGD-95 news was a pisser. Not all participants in dosage group developed liver enzyme increase. Somewhere less than a majority of the 14 in the dosage group. They are still trying to decide to save this one or shelf it in favor of a new agent. But the stock got too cheap for me today and I started a position at $14.75 after selling out last year. I plan to trade it at this point. I anticipate more news flowing (hopefully good news) from the company starting in the second half of the year re the other programs.